Entries by Thomas Gabrielczyk

Sanofi preparing label extension for dupilumab

Positive Phase 3 results with Sanofi/Regeneron‘s IL4/IL-13-targeting antibody dupilumab (Dupixent) in adolescents with moderate-to-severe atopic dermatitis will form the basis of a regulatory submission in this new patient population, according to announcements of Sanofi.

EU approves Shire’s van Willebrand factor

Orphan drug leader Shire plc has been granted EU marketing authorization for its recombinant van Willebrand factor (rVWF) vonicog alfa  as second-line treatment for van Willebrand disease, the most common blot clotting disorder..